Johnson & Johnson Covid-19 vaccines are observed on a table in Los Angeles, May possibly 7, 2021.
Frederic J. Brown | AFP | Getty Photographs
Johnson & Johnson‘s Janssen division, which helped to produce its solitary-dose COVID-19 vaccine, will near considerably of its vaccine investigate and growth functions in the Netherlands, newspaper De Telegraaf noted.
In an emailed response on Wednesday, Johnson & Johnson confirmed strategies to exit some of its vaccine investigate and advancement applications, which it said it had initially disclosed in its 2023 next-quarter outcomes.
“We also constantly evaluate our world wide footprint, such as in the Netherlands, to guarantee it satisfies our present-day and evolving scientific requirements,” Johnson & Johnson mentioned.
De Telegraaf reported that 2,500 individuals worked at Janssen in the Netherlands, a quarter of which were in the area specialising in infectious ailments and vaccines.
It is not distinct how quite a few careers are at possibility.
